The short interest in The Medicines Company (NASDAQ:MDCO) has declined from 13,696,561 on May 31,2016 to 12,560,038 on June 15,2016. The change was measured at 1,136,523 shares or 8.3%. The leftover shorts were 18.5% of the floated shares. The days to cover are 7, given the average daily volume of 1,865,021 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
The Medicines Company (NASDAQ:MDCO): The stock opened at $33.16 on Friday but the bulls could not build on the opening and the stock topped out at $34.42 for the day. The stock traded down to $33.16 during the day, due to lack of any buying support eventually closed down at $33.26 with a loss of -3.71% for the day. The stock had closed at $34.54 on the previous day. The total traded volume was 2,095,465 shares.
The company shares have rallied 16.33% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $43.79 and the one year low was seen on Jul 2, 2015. The 50-Day Moving Average price is $36.07 and the 200 Day Moving Average price is recorded at $34.49.
The Medicines Company (NASDAQ:MDCO) has tumbled 3.12% during the past week and has dropped 11.71% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.51%. The Medicines Company (NASDAQ:MDCO) has underperformed the index by 9.04% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.